Idorsia Ltd
SIX:IDIA

Watchlist Manager
Idorsia Ltd Logo
Idorsia Ltd
SIX:IDIA
Watchlist
Price: 3.7 CHF -8.87% Market Closed
Market Cap: 924.1m CHF

Idorsia Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Idorsia Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Idorsia Ltd
SIX:IDIA
Operating Income
-CHf123.6m
CAGR 3-Years
47%
CAGR 5-Years
22%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Operating Income
-$122.5m
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Operating Income
-$478.1m
CAGR 3-Years
11%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Operating Income
CHf76m
CAGR 3-Years
127%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Operating Income
-CHf2.1m
CAGR 3-Years
40%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Relief Therapeutics Holding SA
SIX:RLF
Operating Income
-CHf19.6m
CAGR 3-Years
20%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
No Stocks Found

Idorsia Ltd
Glance View

Market Cap
861.5m CHF
Industry
Biotechnology

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

IDIA Intrinsic Value
7.85 CHF
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Idorsia Ltd's Operating Income?
Operating Income
-123.6m CHF

Based on the financial report for Sep 30, 2025, Idorsia Ltd's Operating Income amounts to -123.6m CHF.

What is Idorsia Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
22%

Over the last year, the Operating Income growth was 69%. The average annual Operating Income growth rates for Idorsia Ltd have been 47% over the past three years , 22% over the past five years .

Back to Top